Stock DNA
Pharmaceuticals & Biotechnology
USD 17 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.37
-416.52%
1.74
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-62.88%
0%
-62.88%
6 Months
-77.39%
0%
-77.39%
1 Year
-90.29%
0%
-90.29%
2 Years
-97.99%
0%
-97.99%
3 Years
-86.26%
0%
-86.26%
4 Years
-99.56%
0%
-99.56%
5 Years
-99.19%
0%
-99.19%
Beyond Air, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
36.79%
EBIT Growth (5y)
-31.48%
EBIT to Interest (avg)
-21.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.25%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.93
EV to EBIT
-0.29
EV to EBITDA
-0.31
EV to Capital Employed
0.92
EV to Sales
4.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-320.24%
ROE (Latest)
-299.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 16 Schemes (5.56%)
Foreign Institutions
Held by 21 Foreign Institutions (1.65%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1.80
1.20
50.00%
Operating Profit (PBDIT) excl Other Income
-6.70
-6.20
-8.06%
Interest
0.50
0.60
-16.67%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-8.10
-8.10
Operating Profit Margin (Excl OI)
-4,327.80%
-6,226.60%
189.88%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 50.00% vs 9.09% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 39.10% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
3.70
1.20
208.33%
Operating Profit (PBDIT) excl Other Income
-41.00
-60.70
32.45%
Interest
3.00
2.90
3.45%
Exceptional Items
-0.90
0.10
-1,000.00%
Consolidate Net Profit
-48.50
-64.30
24.57%
Operating Profit Margin (Excl OI)
-12,020.80%
-54,363.20%
4,234.24%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 208.33% vs 0.00% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 24.57% vs -8.25% in Mar 2024
About Beyond Air, Inc. 
Beyond Air, Inc.
Pharmaceuticals & Biotechnology
Beyond Air, Inc., formerly AIT Therapeutics, Inc., is a medical device company. The Company is focused on developing a nitric oxide (NO) generator and delivery system that generates NO from ambient air. The Beyond Air NOGDS is designed to deliver a dosage of NO to the lungs. The Company focuses on areas, such as persistent pulmonary hypertension of the newborn (PPHN), bronchiolitis (BRO) and nontuberculous mycobacteria (NTM). Its Beyond Air NOGDS also delivers a high concentration of NO to the lungs. The Company’s products include Beyond Air- PH, Beyond Air- BRO and Beyond Air- NTM.
Company Coordinates 
Company Details
825 E Gate Blvd Ste 320 , GARDEN CITY NY : 11530-2135
Registrar Details






